Bridget-Anne Kirwan

Bridget-Anne Kirwan

Auto-generated profile, based on publicly available information

Bridget-Anne Kirwan

SOCAR Research, Nyon, Switzerland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SAStefan D. Anker
Stefan D. Anker
JCJosep Comin Colet
Josep Comin Colet
GFGerasimos Filippatos
Gerasimos Filippatos
RWRonnie Willenheimer
Ronnie Willenheimer
KDKenneth Dickstein
Kenneth Dickstein
PPPiotr Ponikowski
Piotr Ponikowski
Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 μg per liter or between 100 and 299 μg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780.)

1 July 2011 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
JMJohn E. Morley
John E. Morley
AAAngela Marie Abbatecola
Angela Marie Abbatecola
JAJosep M. Argiles
Josep M. Argiles
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos
JBJuergen Bauer
Juergen Bauer
SAStefan D. Anker
Stefan D. Anker

3 May 2011 in Circulation
Verified
Journal Article
Closed access
FKFriedrich Koehler
Friedrich Koehler
SWSebastian Winkler
Sebastian Winkler
MSMichael Schieber
Michael Schieber
USUdo Sechtem
Udo Sechtem
KSKarl Stangl
Karl Stangl
SAStefan D. Anker
Stefan D. Anker
Background—: This study was designed to determine whether physician-led remote telemedical management (RTM) compared with usual care would result in reduced mortality in ambulatory patients with chronic heart failure (HF). Methods and Results—: We enrolled 710 stable chronic HF patients in New York Heart Association functional class II or III with a left ventricular ejection fraction ≤35% and a history of HF decompensation within the previous 2 years or with a left ventricular ejection fraction ≤25%. Patients were randomly assigned (1:1) to RTM or usual care. Remote telemedical management used portable devices for ECG, blood pressure, and body weight measurements connected to a personal digital assistant that sent automated encrypted transmission via cell phones to the telemedical centers. The primary end point was death from any cause. The first secondary end point was a composite of cardiovascular death and hospitalization for HF. Baseline characteristics were similar between the RTM (n=354) and control (n=356) groups. Of the patients assigned to RTM, 287 (81%) were at least 70% compliant with daily data transfers and no break for >30 days (except during hospitalizations). The median follow-up was 26 months (minimum 12), and was 99.9% complete. Compared with usual care, RTM had no significant effect on all-cause mortality (hazard ratio, 0.97; 95% confidence interval, 0.67 to 1.41; P =0.87) or on cardiovascular death or HF hospitalization (hazard ratio, 0.89; 95% confidence interval, 0.67 to 1.19; P =0.44). Conclusions—: In ambulatory patients with chronic HF, RTM compared with usual care was not associated with a reduction in all-cause mortality. Clinical Trial Registration:—: URL: http://www.ClinicalTrials.gov . Unique identifier: NCT00543881.

1 September 2004 in The Lancet
Verified
Journal Article
Closed access
PPPhilip A Poole-Wilson
Philip A Poole-Wilson
JLJacobus Lubsen
Jacobus Lubsen
BKBridget-Anne Kirwan
Bridget-Anne Kirwan
FDFred J van Dalen
Fred J van Dalen
GWGilbert Wagener
Gilbert Wagener
SWSimon Weber
Simon Weber

16 June 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Stefan D. AnkerStefan D. Anker
Stefan D. Anker
ACAndrew J.S. Coats
Andrew J.S. Coats
GCGabriel Cristian
Gabriel Cristian
DDDinu Dragomir
Dinu Dragomir
EPEnrico Pusineri
Enrico Pusineri
DMDouglas L. Mann
Douglas L. Mann
AUGMENT-HF was an international, multi-centre, prospective, randomized, controlled trial to evaluate the benefits and safety of a novel method of left ventricular (LV) modification with alginate-hydrogel. Alginate-hydrogel is an inert permanent implant that is directly injected into LV heart muscle and serves as a prosthetic scaffold to modify the shape and size of the dilated LV. Patients with advanced chronic heart failure (HF) were randomized (1 : 1) to alginate-hydrogel (n = 40) in combination with standard medical therapy or standard medical therapy alone (Control, n = 38). The primary endpoint of AUGMENT-HF was the change in peak VO2 from baseline to 6 months. Secondary endpoints included changes in 6-min walk test (6MWT) distance and New York Heart Association (NYHA) functional class, as well as assessments of procedural safety. Enrolled patients were 63 ± 10 years old, 74% in NYHA functional class III, had a LV ejection fraction of 26 ± 5% and a mean peak VO2 of 12.2 ± 1.8 mL/kg/min. Thirty-five patients were successfully treated with alginate-hydrogel injections through a limited left thoracotomy approach without device-related complications; the 30-day surgical mortality was 8.6% (3 deaths). Alginate-hydrogel treatment was associated with improved peak VO2 at 6 months—treatment effect vs. Control: +1.24 mL/kg/min (95% confidence interval 0.26–2.23, P = 0.014). Also 6MWT distance and NYHA functional class improved in alginate-hydrogel-treated patients vs. Control (both P < 0.001). Alginate-hydrogel in addition to standard medical therapy for patients with advanced chronic HF was more effective than standard medical therapy alone for improving exercise capacity and symptoms. The results of AUGMENT-HF provide proof of concept for a pivotal trial. NCT01311791.

1 December 2010 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
FKFriedrich Koehler
Friedrich Koehler
SWSebastian Winkler
Sebastian Winkler
MSMichael Schieber
Michael Schieber
USUdo Sechtem
Udo Sechtem
KSKarl Stangl
Karl Stangl
Stefan D. AnkerStefan D. Anker
Stefan D. Anker
Aims: Remote patient management (telemonitoring) may help to detect early signs of cardiac decompensation, allowing optimization of and adherence to treatments in chronic heart failure (CHF). Two meta-analyses have suggested that telemedicine in CHF can reduce mortality by 30–35%. The aim of the TIM-HF study was to investigate the impact of telemedical management on mortality in ambulatory CHF patients. Methods: CHF patients [New York Heart Association (NYHA) II/III, left ventricular ejection fraction (LVEF) ≤35%] with a history of cardiac decompensation with hospitalization in the past or therapy with intravenous diuretics in the prior 24 months (no decompensation required if LVEF ≤ 25%) were randomized 1:1 to an intervention group of daily remote device monitoring (electrocardiogram, blood pressure, body weight) coupled with medical telephone support or to usual care led by the patients’ local physician. In the intervention group, 24/7 physician-led medical support was provided by two central telemedical centres. A clinical event committee blinded to treatment allocation assessed cause of death and reason for hospitalization. The primary endpoint was total mortality. The first secondary endpoint was a composite of cardiovascular mortality or hospitalization due to heart failure. Other secondary endpoints included cardiovascular mortality, all-cause and cause-specific hospitalizations (all time to first event) as well as days lost due to heart failure hospitalization or cardiovascular death (in % of follow-up time), and changes in quality of life and NYHA class. Overall, 710 CHF patients were recruited. The mean follow-up was 21.5 ± 7.2 months, with a minimum of 12 months. Perspective: The study will provide important prospective outcome data on the impact of telemedical management in patients with CHF.